BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

686 related articles for article (PubMed ID: 34367185)

  • 1. Cell Fate Reprogramming in the Era of Cancer Immunotherapy.
    Zimmermannova O; Caiado I; Ferreira AG; Pereira CF
    Front Immunol; 2021; 12():714822. PubMed ID: 34367185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies.
    Datta M; Coussens LM; Nishikawa H; Hodi FS; Jain RK
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():165-174. PubMed ID: 31099649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding and Modulating Immunity With Cell Reprogramming.
    Pires CF; Rosa FF; Kurochkin I; Pereira CF
    Front Immunol; 2019; 10():2809. PubMed ID: 31921109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reprogramming Immune Cells for Enhanced Cancer Immunotherapy: Targets and Strategies.
    Dong Y; Wan Z; Gao X; Yang G; Liu L
    Front Immunol; 2021; 12():609762. PubMed ID: 33968014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy.
    Dai E; Zhu Z; Wahed S; Qu Z; Storkus WJ; Guo ZS
    Mol Cancer; 2021 Dec; 20(1):171. PubMed ID: 34930302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?
    Nixon AB; Schalper KA; Jacobs I; Potluri S; Wang IM; Fleener C
    J Immunother Cancer; 2019 Nov; 7(1):325. PubMed ID: 31775882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
    Matosevic S
    J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.
    Saetersmoen ML; Hammer Q; Valamehr B; Kaufman DS; Malmberg KJ
    Semin Immunopathol; 2019 Jan; 41(1):59-68. PubMed ID: 30361801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic Cell-Based Immunotherapy in Lung Cancer.
    Stevens D; Ingels J; Van Lint S; Vandekerckhove B; Vermaelen K
    Front Immunol; 2020; 11():620374. PubMed ID: 33679709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human iPSC Generation from Antigen-Specific T Cells.
    Nishimura T; Murmann Y; Nakauchi H
    Methods Mol Biol; 2019; 2048():53-57. PubMed ID: 31396928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic Cells and Their Role in Immunotherapy.
    Gardner A; de Mingo Pulido Á; Ruffell B
    Front Immunol; 2020; 11():924. PubMed ID: 32508825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
    Liu Y; Bewersdorf JP; Stahl M; Zeidan AM
    Blood Rev; 2019 Mar; 34():67-83. PubMed ID: 30553527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy Approaches Beyond PD-1 Inhibition: the Future of Cellular Therapy for Head and Neck Squamous Cell Carcinoma.
    Qureshi HA; Lee SM
    Curr Treat Options Oncol; 2019 Mar; 20(4):31. PubMed ID: 30874960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
    Inthagard J; Edwards J; Roseweir AK
    Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized Immuno-Oncology.
    Jain KK
    Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence.
    Huemer F; Leisch M; Geisberger R; Melchardt T; Rinnerthaler G; Zaborsky N; Greil R
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Head and Neck Cancer Immunotherapy beyond the Checkpoint Blockade.
    Heath BR; Michmerhuizen NL; Donnelly CR; Sansanaphongpricha K; Sun D; Brenner JC; Lei YL
    J Dent Res; 2019 Sep; 98(10):1073-1080. PubMed ID: 31340724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy.
    Lei X; Lei Y; Li JK; Du WX; Li RG; Yang J; Li J; Li F; Tan HB
    Cancer Lett; 2020 Feb; 470():126-133. PubMed ID: 31730903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer immunotherapy beyond immune checkpoint inhibitors.
    Marin-Acevedo JA; Soyano AE; Dholaria B; Knutson KL; Lou Y
    J Hematol Oncol; 2018 Jan; 11(1):8. PubMed ID: 29329556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.